Skip to main content
Loading

Oncoteq AG

February 27, 2024
Oncology
Oncoteq AG
Oncoteq is a clinical stage oncology biotech with a focus on first or best-in-class treatments in areas of high unmet need. The company portfolio comprises two highly differentiated assets. TEQ103 has a novel model of action selectively killing ERa+ tumor cells and a potential paradigm shift for patients with hormone receptor positive breast cancers. The second asset, a CD30 directed ADC with an innovative hydrophilic linker is a potential best-in-class treatment for CD30 positive cancers. Both assets are set to enter the clinic in the first half of 2025.
Testimonials

Double Helix


 

Supporting Bank Sponsor


 

Premier Sponsors

Conference Sponsors


 

Sign up for updates

Stay up-to-date on the BIO CEO and Investor Conference via email.

SIGN UP